|By Marketwired .||
|May 15, 2014 07:07 PM EDT||
MISSION VIEJO, CA -- (Marketwired) -- 05/15/14 -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and six months ended March 31, 2014.
The Company reported a net loss of approximately $437,000, or $0.00 per share for the three months ended March 31, 2014. This compares to a net loss of $5,782,000 (including a non-cash adjustment for increases in valuation of warrants of $5,020,000), or $0.06 per share, for the three months ended March 31, 2013.
For the six months ended March 31, 2014, the Company reported a net loss of $1,132,000 or $0.01 per share. This compares to a net loss of $1,755,000 (including a non-cash adjustment for increases in valuation of warrants of $510,000) or $0.03 per share for the six months ended March 31, 2014.
"During the quarter, we continued to make significant progress towards our goal of filing a pre-Emergency Use Authorization application for AEOL 10150 as a treatment for Lung-ARS," stated John L. McManus, President and Chief Executive Officer. "We expect to complete our current study in rhesus macaque monkeys and report top line results in the third calendar quarter of this year. In addition, we will initiate a series of six mouse efficacy studies during May and June, and plan to file our IND by June as well, so that we can initiate a Phase 1 study in healthy human volunteers this fall. These initiatives, combined with our completed safety and efficacy studies, and our achievements in manufacturing under our contract with the Biomedical Advanced Research and Development Authority ("BARDA") should position us well for a pre-Emergency Use Authorization filing."
Key Accomplishments During the Quarter:
- Notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.
- Data published from animal model studies and a pilot efficacy study in non-human primates (NHPs) demonstrating the efficacy of AEOL 10150 as a medical countermeasure (MCM) against the effects of radiation exposure on the lungs. Three papers on studies funded by Aeolus, grant money from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and contract money provided by BARDA were published in the journal Health Physics, volume 106, number 1, in January 2014.
- Significant progress towards developing large-scale, Good Manufacturing Practice capability for producing AEOL 10150, including:
- 90% reduction in manufacturing cost of drug substance achieved; further improvements expected upon scale up of production
- 15,000 vials of final product supplied for human safety studies to support pre-Emergency Use Authorization filing
- 18 months stability demonstrated for final drug product in new formulation at room temperature; stability testing will continue to five years.
As of March 31, 2014, the Company had approximately $520,000 in cash and cash equivalents and 134,550,068 common shares outstanding. The Company had accounts receivable of $1,839,000 and accounts payable of $2,394,000 on March 31, 2014.
On May 5, 2014, the Company executed a Modification of Contract with BARDA. The purpose of the Modification is to (1) make available $1,777,882 in reimbursement to the Company for actual costs incurred under the first three years of its contract with BARDA, (2) establish an increased provisional indirect billing rate for FY2014 and the rest of the BARDA contract period of performance, and (3) establish a cap on the indirect billing rate for the remaining contract period of performance. The Company received payment of the $1,777,882 on May 15, 2014. The effect of the Modification will be (a) to increase the cash balance of the Company and (b) to increase the billing rate for indirect costs under the contract. The Company believes the reimbursement payment and increased billing rates provide sufficient capital to fund operations for approximately two years.
Results of Operations for the Three Months Ended March 31, 2014
Revenue for the three months ended March 31, 2014 was approximately $1,438,000, versus revenue of $859,000 for the three months ended March 31, 2013. The revenue is from the contract with BARDA announced on February 11, 2011. Higher revenue in 2014 reflects both the timing of the initiation of program items as well as revenue recognition under accounting rules.
Research and development expenses increased to approximately $1,173,000 for the three months ended March 31, 2014, from approximately $618,000 for the three months ended March 31, 2013. The increase in 2014 expenses reflects both the timing of the initiation of program items under the BARDA contract as well as expense recognition under accounting rules.
General and administrative expenses were approximately $702,000 for the three months ended March 31, 2014 compared to approximately $1,003,000 for the three months ended March 31, 2014. The lower expense was primarily due to non-recurring costs related to financing in 2013.
Results of Operations for the Six Months Ended March 31, 2014
Revenue for the six months ended March 31, 2014 was approximately $2,231,000, which compares to revenue of $2,201,000 for the six months ended March 31, 2013. The revenue is from the contract with BARDA announced on February 11, 2011. Higher revenue in 2014 reflects both the timing of the initiation of program items as well as revenue recognition under accounting rules.
Research and development expenses increased to approximately $1,880,000 for the six months ended March 31, 2014, from approximately $1,787,000 for the six months ended March 31, 2013. The increase in 2014 expenses reflects both the timing of the initiation of program items under the BARDA contract as well as expense recognition under accounting rules.
General and administrative expenses were approximately $1,503,000 for the six months ended March 31, 2014 compared to approximately $1,659,000 for the six months ended March 31, 2014. The lower expense was primarily due to absence of non-recurring costs related to financing in 2013.
Corporate Update Conference Call Information
Aeolus will host a conference call on Monday, May 19th at 11:00 a.m. ET to outline the Company's achievements in the second fiscal quarter of 2014 and provide an update on the progress made to date on the BARDA contract and other biodefense development programs. Interested parties may participate by dialing (855) 644-8125 (US) or (779) 232-4780 (International), approximately five to ten minutes before the call start time. A replay of the call will be available starting on May 19, 2014, at 2:00 p.m. ET through June 19, 2014, at 11:59 p.m. ET. Interested parties may access the replay by dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering conference ID number 46809798. An archived webcast of the conference call will be available for 90 days on the Investors page of the Aeolus Pharmaceuticals web site at www.aolsrx.com.
Aeolus has filed today with the SEC its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. Aeolus urges its investors to read this quarterly filing as well as its Annual Report on Form 10-K, also filed with the SEC, for further details concerning the Company. The Quarterly Report on Form 10-Q and the Annual Report on Form 10-K are also available on the Company's website, at www.aolsrx.com.
About AEOL 10150
AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure. AEOL 10150 may have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation in the treatment of oncology.
AEOL 10150 has performed well in preclinical and non-clinical studies, demonstrating statistically significant survival benefit in an acute radiation-induced lung injury model, and was well-tolerated in two human clinical trials. The Company believes it could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation, whether from cancer therapy or a nuclear event.
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology. For more information, please visit Aeolus's corporate website at www.aolsrx.com.
The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs, the Company's potential initiation of large efficacy studies in mice and NHPs, as well as a phase 1 study in healthy normal volunteers, the BARDA Contract, and the expected use of proceeds from the financing. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies, and whether BARDA exercises one or more additional options under the BARDA Contract. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2013. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
AEOLUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except per share data) March 31, September 30, 2014 2013 ------------- ------------- ASSETS Current assets: Cash and cash equivalents $ 520 $ 869 Accounts receivable 1,839 370 Deferred subcontractor cost 1,402 656 Prepaids and other current assets 96 39 ------------- ------------- Total current assets 3,857 1,935 Investment in CPEC LLC 32 32 ------------- ------------- Total assets $ 3,889 $ 1,966 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 2,394 $ 579 Deferred revenue 1,458 682 ------------- ------------- Total current liabilities 3,852 1,261 ------------- ------------- Total liabilities 3,852 1,261 Commitments and Contingencies (Note F) Stockholders' equity: Preferred stock, $.01 par value per share, 10,000,000 shares authorized: Series A nonredeemable convertible preferred stock, 1,250,000 shares authorized as of March 31, 2014 and September 30, 2013, respectively; no shares issued and outstanding as of March 31, 2014 and September 30, 2013, respectively -- -- Series B nonredeemable convertible preferred stock, 1,600,000 and 1,600,000 shares authorized as of March 31, 2014 and September 30, 2013, respectively; 526,080 and 526,080 shares issued and outstanding as of March 31, 2014 and September 30, 2013, respectively 5 5 Common stock, $.01 par value per share, 200,000,000 shares authorized; 134,550,068 shares issued and outstanding as of March 31, 2014 and September 30, 2013, respectively 1,346 1,346 Additional paid-in capital 183,739 183,276 Accumulated deficit (185,053) (183,922) ------------- ------------- Total stockholders' equity 37 705 ------------- ------------- Total liabilities and stockholders' equity $ 3,889 $ 1,966 ============= =============
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
AEOLUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three months Ended Six Months Ended March 31, March 31, -------------------- -------------------- 2014 2013 2014 2013 --------- --------- --------- --------- Revenue: Contract Revenue $ 1,438 $ 859 $ 2,231 $ 2,201 Costs and expenses: Research and development 1,173 618 1,880 1,787 General and administrative 702 1,003 1,483 1,659 --------- --------- --------- --------- Total costs and expenses 1,875 1,621 3,363 3,446 --------- --------- --------- --------- Loss from operations (437) (762) (1,132) (1,245) Non-cash financing charges and change in fair value of warrants (Note B) -- (5,020) -- (510) --------- --------- --------- --------- Net loss $ (437) $ (5,782) $ (1,132) $ (1,755) ========= ========= ========= ========= Net loss per weighted share attributable to common stockholders: Basic (Note D) $ 0.00 $ (0.06) $ (0.01) $ (0.03) ========= ========= ========= ========= Diluted (Note D) $ 0.00 $ (0.06) $ (0.01) $ (0.03) ========= ========= ========= ========= Weighted average common shares outstanding: Basic 134,550 94,425 134,550 69,664 ========= ========= ========= ========= Diluted 134,550 94,425 134,550 69,664 ========= ========= ========= =========
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
AEOLUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands) Six Months Ended March 31, ---------------------------- 2014 2013 ------------- ------------- Cash flows from operating activities: Net loss $ (1,132) $ (1,755) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 463 309 Change in fair value of warrants -- 510 Change in assets and liabilities: Accounts receivable (1,468) (738) Deferred subcontractor cost (746) (1,005) Prepaid and other assets (57) (31) Accounts payable and accrued expenses 1,815 (249) Deferred revenue 776 1,046 ------------- ------------- Net cash used in operating activities (349) (1,913) ------------- ------------- Cash flows provided by financing activities: Proceeds from issuance of common stock and warrants -- 3,616 Costs related to the issuance of common stock and warrants -- (58) ------------- ------------- Net cash provided by financing activities -- 3,558 ------------- ------------- Net decrease in cash and cash equivalents (349) 1,645 Cash and cash equivalents at beginning of period 869 281 ------------- ------------- Cash and cash equivalents at end of period $ 520 $ 1,926 ============= ============= Supplemental disclosure of cash flow information: State income taxes $ -- $ -- ============= =============
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
President and Chief Executive Officer
Aeolus Pharmaceuticals, Inc.
The cloud. Like a comic book superhero, there seems to be no problem it can’t fix or cost it can’t slash. Yet making the transition is not always easy and production environments are still largely on premise. Taking some practical and sensible steps to reduce risk can also help provide a basis for a successful cloud transition. A plethora of surveys from the likes of IDG and Gartner show that more than 70 percent of enterprises have deployed at least one or more cloud application or workload. Y...
Nov. 27, 2015 01:00 AM EST Reads: 450
PubNub has announced the release of BLOCKS, a set of customizable microservices that give developers a simple way to add code and deploy features for realtime apps.PubNub BLOCKS executes business logic directly on the data streaming through PubNub’s network without splitting it off to an intermediary server controlled by the customer. This revolutionary approach streamlines app development, reduces endpoint-to-endpoint latency, and allows apps to better leverage the enormous scalability of PubNu...
Nov. 27, 2015 01:00 AM EST Reads: 295
Microservices are a very exciting architectural approach that many organizations are looking to as a way to accelerate innovation. Microservices promise to allow teams to move away from monolithic "ball of mud" systems, but the reality is that, in the vast majority of organizations, different projects and technologies will continue to be developed at different speeds. How to handle the dependencies between these disparate systems with different iteration cycles? Consider the "canoncial problem"...
Nov. 27, 2015 01:00 AM EST Reads: 418
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it! In her Day 2 Keynote at 17th Cloud Expo, San...
Nov. 27, 2015 01:00 AM EST Reads: 541
Apps and devices shouldn't stop working when there's limited or no network connectivity. Learn how to bring data stored in a cloud database to the edge of the network (and back again) whenever an Internet connection is available. In his session at 17th Cloud Expo, Ben Perlmutter, a Sales Engineer with IBM Cloudant, demonstrated techniques for replicating cloud databases with devices in order to build offline-first mobile or Internet of Things (IoT) apps that can provide a better, faster user e...
Nov. 27, 2015 12:45 AM EST Reads: 392
Container technology is shaping the future of DevOps and it’s also changing the way organizations think about application development. With the rise of mobile applications in the enterprise, businesses are abandoning year-long development cycles and embracing technologies that enable rapid development and continuous deployment of apps. In his session at DevOps Summit, Kurt Collins, Developer Evangelist at Built.io, examined how Docker has evolved into a highly effective tool for application del...
Nov. 27, 2015 12:00 AM EST Reads: 332
I recently attended and was a speaker at the 4th International Internet of @ThingsExpo at the Santa Clara Convention Center. I also had the opportunity to attend this event last year and I wrote a blog from that show talking about how the “Enterprise Impact of IoT” was a key theme of last year’s show. I was curious to see if the same theme would still resonate 365 days later and what, if any, changes I would see in the content presented.
Nov. 26, 2015 10:00 PM EST Reads: 392
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Nov. 26, 2015 04:00 PM EST Reads: 382
Internet of @ThingsExpo, taking place June 7-9, 2016 at Javits Center, New York City and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo New York Call for Papers is now open.
Nov. 26, 2015 03:30 PM EST Reads: 525
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty ...
Nov. 26, 2015 03:15 PM EST Reads: 521
We are rapidly moving to a brave new world of interconnected smart homes, cars, offices and factories known as the Internet of Things (IoT). Sensors and monitoring devices will touch every part of our lives. Let's take a closer look at the Internet of Things. The Internet of Things is a worldwide network of objects and devices connected to the Internet. They are electronics, sensors, software and more. These objects connect to the Internet and can be controlled remotely via apps and programs. ...
Nov. 26, 2015 02:15 PM EST Reads: 499
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, explored the IoT cloud-based platform technologies driving t...
Nov. 26, 2015 01:00 PM EST Reads: 392
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
Nov. 26, 2015 01:00 PM EST Reads: 291
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
Nov. 26, 2015 12:00 PM EST Reads: 151
As organizations shift towards IT-as-a-service models, the need for managing & protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection & E-Discovery of your data - whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise.
Nov. 26, 2015 11:30 AM EST Reads: 121